DeutschNewstral
Article
Mmarketwatch.com on 2019-03-13 15:40
Akari Therapeutics' stock rockets on massive volume after 'successful' pre-IND FDA meeting
Related news
- MAkari Therapeutics' stock rockets on heavy volume after FDA grants nomacopan 'Fast Track' designationmarketwatch.com
- MAkari Therapeutics shares soar 13% premarket after FDA grants Orphan Drug designation to nomacopanmarketwatch.com
- MFate Therapeutics stock up 11% after FDA clears IND applicationmarketwatch.com
- MNabriva Therapeutics' stock soars in heavy volume after FDA approves NDA for CABP treatmentmarketwatch.com
- MMelinta Therapeutics' stock rockets on heavy volume after FDA accepts sNDA for Baxdelamarketwatch.com
- MShares of Fate Therapeutics up 4.1% in premarket trade after FDA accepts IND application for potential cancer treatmentmarketwatch.com
FDA Approves Sage Therapeutics’ Zulressowsj.com
FDA OKs United Therapeutics’ cancer drugthedailyrecord.com
United Therapeutics scores another FDA approvalbizjournals.com- MSarepta Therapeutics stock tanks after drug's FDA committee reviewmarketwatch.com
- MSarepta Therapeutics shares dive on safety issues in FDA databasemarketwatch.com
- FDA advisory panel recommends approval of Spark Therapeutics' gene therapybizjournals.com
- MPTC Therapeutics gains after FDA panel votes against drug approvalmarketwatch.com
Spark Therapeutics Gene Therapy for Blindness Moves Forward With FDAphillymag.com- Newest FDA approval could boost Partner Therapeutics' Lynnwood plantbizjournals.com
FDA fast tracks SpringWorks Therapeutics drug for treatment of tumorswestfaironline.com- HSPR Therapeutics wins FDA approval for pain treatment systemhome.crainscleveland.com
- BNeos Therapeutics stock soars on FDA approval for ADHD drugbizbeatblog.dallasnews.com
- United Therapeutics’ 2020 plan: ‘No fewer’ than 3 FDA approvalsbizjournals.com